Etiqueta: multiple sclerosis

Opexa Therapeutics shows strong preclinical data for its autologous adult stem cell diabetes therapy.

Mothers of toddlers in England are being encouraged to store the baby teeth of their children as a future source of stem cells.

Dr. Bernardine Healy has written an article in U.S. News and World Report entitled Why Embryonic Stem Cells Are Obsolete.

Researchers at Northwestern University have once again achieved encouraging results in the treatment of multiple sclerosis with adult stem cells.

Doctors in Chicago use adult stem cells derived from bone marrow to halt and reverse the progression of multiple sclerosis.

Opexa Therapeutics holds an informative briefing on both executive and scientific company news.

Celgene Cellular Therapeutics receives FDA authorization to commence the first clinical trials ever to be conducted in the U.S. with adult stem cells derived from placental blood.

Opexa Therapeutics is scheduled to present an overview of its T-cell and adult stem cell therapies for autoimmune diseases at an annual health care conference.

The biotech company Pluristem Therapeutics has developed an adult stem cell product for the prevention of clinical symptoms of multiple sclerosis.

The biotech company Pluristem Therapeutics Inc., specializing in adult stem cells, has been chosen to present at the First Annual Israeli Presidential Conference.